Pharmacoeconomic Analysis Of Uncomplicated Hypertension In Ambulatory Care Clinic
dc.contributor.author | Ahmad Al-Efan, Qais Mohammad | |
dc.date.accessioned | 2019-09-05T07:59:18Z | |
dc.date.available | 2019-09-05T07:59:18Z | |
dc.date.issued | 2011-02 | |
dc.description.abstract | Abnormal elevation in BP is associated with cardiovascular and renal diseases. Prevalence of hypertension in subjects aged ≥ 15 years is 27.8% in Malaysia. Studies have reported high direct and indirect costs are attributable to hypertension. Pharmacoeconomics implements and applies methodologies of health economics to the field of pharmaceuticals and pharmaceutical policy. Malaysia lacks data on how much it cost to treat hypertension and what is the size of the economic burden of hypertension. This study was done to: 1) estimate the cost of treating uncomplicated hypertension, 2) estimate the impact of uncontrolled BP on ambulatory care resources, and 3) evaluate the cost-effectiveness of different antihypertensive drug classes. Prospective data collection of a cohort of hypertensive patients who had signed the informed consent sheet and followed up for one year were analyzed retrospectively to determine the costs (direct and indirect) attributable to uncomplicated hypertension. Cost-effectiveness ratios of different antihypertensive drug classes were calculated and compared. Nonparametric tests (i.e., Kruskal Wallis and Mann-Whitney) were used to determine the statistically significant differences in costs and a p value of < 0.05 was defined as statistically significant. | en_US |
dc.identifier.uri | http://hdl.handle.net/123456789/8836 | |
dc.language.iso | en | en_US |
dc.publisher | Universiti Sains Malaysia | en_US |
dc.subject | Uncomplicated Hypertension | en_US |
dc.subject | Ambulatory Care Clinic | en_US |
dc.title | Pharmacoeconomic Analysis Of Uncomplicated Hypertension In Ambulatory Care Clinic | en_US |
dc.type | Thesis | en_US |
Files
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: